This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BioMarin's (BMRN) Voxzogo Expanded Label Filing Accepted by EMA
by Zacks Equity Research
The EMA validates BioMarin's (BMRN) label expansion filing for Voxzogo to treat children under two years with achondroplasia. BMRN submits a filing for using Voxzogo in children under five years.
Why Is Horizon Therapeutics (HZNP) Up 38.3% Since Last Earnings Report?
by Zacks Equity Research
Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Incyte (INCY) Up 3.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is BioMarin (BMRN) Up 14.1% Since Last Earnings Report?
by Zacks Equity Research
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioMarin (BMRN) Up After FDA Scraps AdCom Meet for BLA Filing
by Zacks Equity Research
The FDA decides not to hold an advisory committee meeting for BioMarin Pharmaceuticals' (BMRN) regulatory filing seeking approval for hemophilia A gene therapy, valrox.
BioMarin (BMRN) Q3 Earnings Beat, Sales Miss, Ups Voxzogo View
by Zacks Equity Research
BioMarin Pharmaceutical's (BMRN) third-quarter 2022 earnings beat estimates, but sales slightly miss the mark.
BioMarin Pharmaceutical (BMRN) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of 21.62% and 1.53%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
CRISPR (CRSP) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
CRSIPR Therapeutics (CRSP) is expected to update its pipeline candidates, specifically exa-cel, its lead candidate, in its third-quarter earnings.
Sanofi (SNY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Sanofi's (SNY) top line is likely to have been driven by higher sales of Dupixent and vaccines.
Can BioMarin (BMRN) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Eliquis, Opdivo Fuel Bristol-Myers (BMY) Q3 Earnings?
by Zacks Equity Research
Investors are likely to focus on the demand for Eliquis and Opdivo along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q3 results. Operating expenses might have jumped.
Merck (MRK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, and COVID-19 antiviral pill, molnupiravir when the company reports Q3 earnings.
Assertio (ASRT) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Assertio Holdings' (ASRT) third-quarter performance is likely to reflect the sales performance of its marketed drugs and cost savings from the company's restructuring plans.
Universal Health (UHS) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Universal Health's (UHS) Q3 results are likely to reflect sound segmental performances resulting from a constant pursuit of expansion moves. However, high labor costs might partly offset the results.
4 Biotech Stocks Set to Outpace Q3 Earnings Estimates
by Sundeep Ganoria
Let us take a look at some biotech stocks, ARGX, BMRN, LLY and GMAB, which are poised to beat on third-quarter earnings.
What's in Store for Novartis (NVS) This Earnings Season?
by Zacks Equity Research
Investors will focus on the regular top and bottom-line numbers along with updates on the Sandoz spin-off when Novartis (NVS) reports third-quarter 2022 results.
Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q3 Earnings Expected to Decline
by Zacks Equity Research
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AVEO Pharmaceuticals (AVEO) Inks Deal to be Acquired by LG Chem
by Zacks Equity Research
Aveo Pharmaceuticals (AVEO) is set to be acquired by LG Chem for an aggregate amount of $566 billion. The deal is expected to close by early 2023. Stock up.
Akouos (AKUS) Surges on $610M Buyout Deal With Eli Lilly
by Zacks Equity Research
Akouos (AKUS) is set to be acquired by Eli Lilly for an aggregate amount of $610 million. The deal is expected to close in the fourth quarter of 2022. Stock up.
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Milestone's (MIST) Tachycardia Study Data Fail to Impress Investors
by Zacks Equity Research
Milestone (MIST) reports positive top-line results from its late-stage study evaluating its lead candidate, etripamil, in patients with paroxysmal supraventricular tachycardia. The results fail to impress investors.
Factors Setting the Tone for HCA Healthcare (HCA) Q3 Earnings
by Zacks Equity Research
HCA Healthcare's (HCA) third-quarter results are expected to reflect better emergency room visits and outpatient surgeries, partly offset by the continued incidence of labor costs.
Here's Why You Should Add Intra-Cellular Therapeutics (ITCI) Stock Now
by Zacks Equity Research
Intra-Cellular's (ITCI) product revenues are primarily driven by higher sales of its schizophrenia and bipolar disorder drug Caplyta. Caplyta is also being evaluated for other CNS indications.
BioMarin (BMRN) Hemophilia Gene Therapy BLA Gets FDA Acceptance
by Zacks Equity Research
If approved, BioMarin's (BMRN) valoctocogene roxaparvovec will become the first gene therapy for treating hemophilia A in the United States. A decision from the FDA is due on Mar 31, 2023.
Wall Street Analysts See a 31% Upside in BioMarin (BMRN): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for BioMarin (BMRN) points to a 30.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.